Johnson & Johnson other cardiovascular — Sales to Customers remained flat by 0.0% to $99.25M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 4.5%, from $95.00M to $99.25M. Over 3 years (FY 2022 to FY 2025), other cardiovascular — Sales to Customers shows an upward trend with a 6.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growing market adoption or successful commercialization of specialized cardiovascular products, while a decrease may signal market saturation or competitive pressure in these niche areas.
This metric represents the total revenue generated from the sale of cardiovascular medical devices and related products...
Peers in the medical device industry typically report similar revenue streams under specialized cardiovascular or 'other' medical technology segments.
jnj_segment_other_cardiovascular_sales_to_customers| FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|
| Value | $332.00M | $356.00M | $380.00M | $397.00M |
| YoY Change | — | +7.2% | +6.7% | +4.5% |